You are here: Home: HOU 1 | 2009 Audio: HOU 1 | 2009
 
 
 

Go to interview with Gail J Roboz, MD
Go to interview with Stephanie A Gregory, MD
Go to interview with Sundar Jagannath, MD
Go to interview with Guillermo Garcia-Manero, MD

Go to Bonus Audio


 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

     
Gail J Roboz, MD
Associate Professor of Medicine
Director, Leukemia Program
Weill Medical College of
Cornell University
The New York Presbyterian Hospital
New York, New York


 
  Click here to download the entire interview  
Track 1 Pathobiology of myelodysplastic syndrome (MDS)
Track 2 Clinical evaluation of patients with MDS
Track 3 Treatment algorithm for patients with MDS
Track 4 Using the International Prognostic Scoring System (IPSS) to determine treatment options for MDS
Track 5 Duration of therapy and tolerability of azacitidine
Track 6 AZA-001: A Phase III trial of azacitidine versus conventional care regimens for patients with higher-risk MDS

Track 7 Magnitude of benefit associated with azacitidine in MDS
Track 8 Clinical use of azacitidine and decitabine for MDS
Track 9 Management of MDS in a tertiary care setting
Track 10 Debunking the concept of age-related anemia and failing to refer patients for diagnostic workup
Track 11 Overall survival rates for patients with acute myelogenous leukemia (AML)
Track 12 Clinical trials for AML
Track 13 Complexities in the management of AML
Track 14 Future directions in clinical trials for patients with MDS
     
Stephanie A Gregory, MD
The Elodia Kehm Chair of Hematology
Professor of Medicine
Director, Section of Hematology
Rush University Medical Center/Rush
University
Chicago, Illinois


 
  Click here to download the entire interview  
Track 1 Case discussion: A 34-year-old woman with asymptomatic, Grade I follicular lymphoma
Track 2 Role of transplantation for follicular lymphoma
Track 3 Novel humanized anti-CD20 monoclonal antibody ofatumumab in the treatment of non-Hodgkin lymphoma (NHL)
Track 4 Clinical experience with ofatumumab with CHOP in the treatment of NHL
Track 5 Ofatumumab for relapsed/refractory chronic lymphocytic leukemia (CLL)
Track 6 Future directions for the development of ofatumumab in the treatment of CLL
Track 7 Phase III trial of R-bendamustine versus R-CHOP as first-line therapy for follicular, indolent or mantle-cell lymphoma (MCL)

Track 8 First-line therapy for follicular lymphoma
Track 9 RESORT trial of maintenance rituximab for low tumor burden, indolent lymphoma
Track 10 Clinical use of maintenance rituximab for follicular lymphoma
Track 11 Clinical data with bortezomib for follicular lymphoma
Track 12 Case discussion: An 87-year-old woman with Richter’s transformation from CLL
Track 13 Lenalidomide for the treatment of CLL
Track 14 Case discussion: A 60-year-old man with Stage IV MCL
Track 15 Therapeutic approach for patients with MCL
Track 16 Clinical use of bortezomib for relapsed MCL
Track 17 Maintenance rituximab for MCL
Track 18 Case discussion: A 60-year-old woman with diffuse large B-cell lymphoma (DLBCL)
Track 19 Treatment strategies being evaluated in DLBCL
Track 20 Clinical use of dose-dense regimens for DLBCL
Track 21 Utilization of radioimmunotherapy for DLBCL
Track 22 GCLLSG-CLL8: A Phase III trial of FC versus FCR as first-line therapy for CLL
     
Sundar Jagannath, MD
Chief, Multiple Myeloma and
Stem Cell Transplantation Program
St Vincent’s Comprehensive
Cancer Center
New York, New York
Professor of Medicine
New York Medical College
Valhalla, New York
 
  Click here to download the entire interview  
Track 1 Combination regimens incorporating bortezomib for patients with newly diagnosed multiple myeloma (MM)
Track 2 Clinical use of bortezomib-containing regimens in patients with high-risk MM
Track 3 Safety and efficacy of lenalidomide/bortezomib/dexamethasone (RVD) in patients with newly diagnosed MM
Track 4 Case discussion: Therapeutic approach for a 68-year-old woman with relapsed MM four years after treatment with VAD followed by a stem cell transplant
Track 5 Clinical trial of lenalidomide/dexamethasone with elotuzumab for relapsed MM
Track 6 Clinical trial of bortezomib with vorinostat for relapsed/refractory MM

Track 7 Case discussion: An 80-year-old man with newly diagnosed Stage II MM
Track 8 Case discussion: A 55-year-old man with slowly progressing MM
Track 9 Case discussion: A 68-year-old woman with relapsed MM who previously received front-line VAD induction therapy
     
Guillermo Garcia-Manero, MD
Associate Professor of Medicine
Chief, Section of Myelodysplastic
Syndromes
Department of Leukemia
The University of Texas MD Anderson
Cancer Center
Houston, Texas
 
  Click here to download the entire interview  
Track 1 Therapeutic approaches for elderly patients with AML
Track 2 Clinical trial data with clofarabine for AML and MDS
Track 3 Clinical use of clofarabine off protocol for MDS or AML
Track 4 Side effects and toxicities associated with clofarabine
Track 5 Acute promyelocytic leukemia (APL)
Track 6 All-trans retinoic acid (ATRA) and arsenic trioxide for APL

Track 7 Side effects and toxicities associated with ATRA and arsenic trioxide
Track 8 Induction and consolidation with ATRA and arsenic trioxide for APL
Track 9 Molecular monitoring for APL
Track 10 Key published data sets in APL
     
Bonus interview with:
Guillermo Garcia-Manero, MD

Associate Professor of Medicine
Chief, Section of Myelodysplastic Syndromes
Department of Leukemia
The University of Texas MD Anderson
Cancer Center
Houston, Texas
 
  Click here to download the entire bonus interview  
Track 1 Is myelodysplastic syndrome (MDS) cancer?
Track 2 Incidence and demographics of MDS
Track 3 Diagnosis and risk assessment of MDS
Track 4 Selection of treatment for low-risk disease
Track 5 Effects of hypomethylating agents
Track 6 Clinical trials of decitabine for MDS

Track 7 Azacitidine versus decitabine in the clinical management of MDS